A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects with Relapsed and Refractory Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Relapsed and refractory multiple myeloma
- Registration Number
- JPRN-jRCT2051230108
- Lead Sponsor
- Hayakawa Jin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
History of multiple myeloma with relapsed and refractory disease
-Eastern Cooperative Oncology Group Performance Status of 0 or 1
-Must have measurable disease as determined by the central laboratory
Exclusion Criteria
-Symptomatic central nervous system involvement of multiple myeloma
-Prior autologous stem cell transplant <= 3 months prior
-Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning <= 12 months prior
-History of concurrent second cancers requiring active, ongoing systemic treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the safety and tolerability of CC-93269, in subjects with relapsed and refractory MM.
- Secondary Outcome Measures
Name Time Method To evaluate the preliminary efficacy of CC-93269 in relapsed and refractory MM, etc.